Cantor Fitzgerald Raises Pfizer (PFE) PT to $27 Amid Shifting Obesity Data Focus

Group 1 - Pfizer Inc. is considered one of the most undervalued large-cap stocks currently, with Cantor Fitzgerald raising its price target to $27 from $24 while maintaining a Neutral rating [1] - The firm anticipates a relatively quiet earnings call for Pfizer, focusing on the timing and framing of VESPER-3 obesity data, as 2026 guidance has already been established with modest beat-and-raise potential expected [1] - Incremental updates regarding the Lyme disease vaccine, mevro for prostate cancer, and sigvotatug vedotin for non-small cell lung cancer are expected to be more influential than the Q4 2025 results [2] Group 2 - Pfizer announced positive results from Cohort 3 of the pivotal Phase 3 BREAKWATER trial, showing a confirmed objective response rate of 64.4% for BRAFTOVI in combination with cetuximab and FOLFIRI, compared to 39.2% for the standard-of-care regimen [3] - The findings from the BREAKWATER trial suggest that the BRAFTOVI combination provides a durable response and potential flexibility in chemotherapy backbones for treating BRAF V600E-mutant metastatic colorectal cancer [3] Group 3 - Pfizer Inc. is involved in the discovery, development, manufacturing, marketing, distribution, and sale of biopharmaceutical products both in the US and internationally, offering medicines and vaccines across various therapeutic areas [4]